Theriva Biologics, Inc. (TOVX) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
TOVX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Theriva Biologics, Inc. (TOVX) trades at a price-to-earnings ratio of -0.2x, with a stock price of $0.35 and trailing twelve-month earnings per share of $-0.56.
Compared to the Healthcare sector median P/E of 22.2x, TOVX trades at a 101% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, TOVX trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TOVX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TOVX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $234M | 4.7Lowest | 4.67Best | +49%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See TOVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TOVX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TOVX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTOVX — Frequently Asked Questions
Quick answers to the most common questions about buying TOVX stock.
Is TOVX stock overvalued or undervalued?
TOVX current P/E: -0.2x. 5-year average P/E: N/A. Percentile: N/A.
How does TOVX's valuation compare to peers?
Theriva Biologics, Inc. P/E of -0.2x compares to sector median of 22.2x. The discount suggests lower growth expectations or higher risk.
What is TOVX's PEG ratio?
TOVX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.